Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

August 31, 2013

Conditions
Adenovirus InfectionEBV Infection
Interventions
BIOLOGICAL

Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection

"Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."

Trial Locations (8)

27710

Duke University Medical Center, Durham

77030

MD Anderson Cancer Center, Houston

Texas Children's Hospital, Houston

77073

Houston Methodist Hospital, Houston

90027

Children's Hospital of Los Angeles, Los Angeles

Unknown

University of Miami, Coral Gables

Hackensack University, Bergen County

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

National Marrow Donor Program

OTHER

collaborator

The Emmes Company, LLC

INDUSTRY

collaborator

Duke University

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Children's Hospital Los Angeles

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Boston Children's Hospital

OTHER

collaborator

University of Miami

OTHER

collaborator

Hackensack Meridian Health

OTHER

collaborator

University of California, Los Angeles

OTHER

lead

Baylor College of Medicine

OTHER

NCT00711035 - Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) | Biotech Hunter | Biotech Hunter